Catatonia was first described in 1874 by Karl Ludwig Kahlbaum in *"Die Katatonie oder das Spannungsirresein,"* ("Catatonia or tension-insanity").\[[@ref1]\] The current *Diagnostic and Statistics Manual* (DSM-TR-IV) and DSM-V describe catatonia, not as a separate disorder, but as a subtype of an underlying disorder (cf. "with psychotic features").\[[@ref2][@ref3]\] The essential features of catatonia are marked psychomotor disturbance. The clinical picture is dominated by at least two of five pathological signs: (1) Motor immobility, (2) excess motor activity, (3) extreme negativism or mutism, (4) peculiarities of voluntary movement, and (5) echolalia or echopraxia. In the late 19^th^ century, the prevalence in hospitalized psychiatric patients ranged from 6% to 38%.\[[@ref2]\] The current incidence in psychiatric inpatients is estimated at 5%-20%. However, primarily due to a lack of recognition and knowledge, catatonia might be grossly underdiagnosed.\[[@ref4]\] Described predominantly in schizophrenia, catatonia was long believed to be unique to this disorder.\[[@ref1]\] We now know this to be incorrect: It is seen in a wide range of psychiatric and medical conditions. Most cases (25%-50%) occur in mood disorders, 10% in schizophrenia, and the rest in other mental disorders.\[[@ref5]\] Moreover, catatonia can (1) occur in various metabolic, neurological, and infectious diseases, (2) be a side effect of medication, and is (3) notorious in neuroleptic malignant syndrome, Stauder\'s lethal Catatonia, and anti-NMDA receptor encephalitis.\[[@ref1]\]

Although catatonia has been around for a long time, data regarding its treatment with psychotropic medication in bipolar disorder remain scarce. (*Pubmed search April 2014 with MeSH terms "catatonia"/AND/"mood disorders/OR/bipolar disorders" resulted in 294 hits. Nine of which were clinical trials, including only two regarding pharmacologic treatment of catatonia in bipolar disorder*).

Data on pharmacologic treatment of catatonia in bipolar disorder in rural practice are almost nonexistent.

The current case report of colleague Muneer entitled "Catatonia in a patient with bipolar disorder type I,"\[[@ref6]\] is therefore very welcome. It describes a postmenopausal woman with a lifelong history of bipolar disorder developing catatonia during a depressed episode, her refractoriness to conventional mood stabilizers, and finally her response to levetiracetam \[Keppra, Union chimique belge inc\] in a dose of 750 mg twice daily. The motivation to select this drug was manifold: (1) Lorazepam (effective in treating catatonia) in its parenteral form was unavailable; (2) the treatment team had no experience with this treatment; (3) the patient showed refractoriness to conventional mood stabilizers; and (4) levetiracetam was available. Levetiracetam ((S)-α-ethyl-2-oxo-1-pyrrolidine acetamide) is a pyrrolidonderivate and has a favorable pharmacokinetic profile, the drug is only partly metabolized (24%, to an inactive metabolite) and is excreted through the kidneys.\[[@ref7]\] It is generally well tolerated, but possible side effects include nasopharyngitis, headaches, drowsiness, and fatigue. It is a potential mood stabilizer as well, due to its effect on glutamate and GABA. The mechanism of action is not fully understood but *in vitro* assays on crude membranes suggest that levetiracetam selectively binds to brain cell membranes in a reversible, saturable, and stereoselective fashion.\[[@ref7]\] In India, it is relatively inexpensive as well (lowest price found: 49 Indian Rupees, 0,81 US dollar per 10 tablets 250 mg).

The strength of this article resides in the clear and unique case description, the well-justified choice of levetiracetam, and of course the successful patient outcome. There are weaknesses as well, which are addressed by the authors themselves: (1) Serum carbamazepine and valproate levels were not part of the laboratory workup, leaving it unclear if the patient showed refractoriness to these drugs with normal serum levels, or received a too low dosage. (2) Psychiatric evaluation was only used to assess the catatonic state and not in combination with a standardized catatonia tool as well, possibly leading to observer variability. Two final remarks: (1) Catatonia induced by levetiracetam has also been described.\[[@ref8]\] (2) Because levetiracetam, used as a mood stabilizer, has not been extensively researched, it remains unclear if levetiracetam truly is effective and safe in treating catatonia in bipolar disorder. After all: one result is no result and the favorable outcome can simply be a benign natural course. We will always need confirmation studies before a new finding can become a scientific fact.

This case report is a further, but small, step in exploring other treatment options of catatonia in bipolar disorder. Specifically in rural practice, where certain treatment options frequently are unavailable. It also offers a possible new treatment for patients who refuse electroconvulsive therapy, or have a contraindication for this procedure. A lot of questions regarding catatonia and its treatment are still unanswered but the author has provided us with a new possible treatment that deserves further exploration. For this, we are grateful to the author and editor, and we conclude with Cicero\'s "Quid deinde" ("What is next"?).
